Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EBIT: 2009-2024

Historic EBIT for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $41.9 million.

  • Tg Therapeutics' EBIT rose 136.17% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 20452.28%. This contributed to the annual value of $41.9 million for FY2024, which is 103.21% up from last year.
  • Per Tg Therapeutics' latest filing, its EBIT stood at $41.9 million for FY2024, which was up 103.21% from $20.6 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' EBIT registered a high of $41.9 million during FY2024, and its lowest value of -$344.8 million during FY2021.
  • Its 3-year average for EBIT is -$51.9 million, with a median of $20.6 million in 2023.
  • In the last 5 years, Tg Therapeutics' EBIT plummeted by 61.84% in 2020 and then surged by 109.45% in 2023.
  • Yearly analysis of 5 years shows Tg Therapeutics' EBIT stood at -$273.6 million in 2020, then fell by 26.02% to -$344.8 million in 2021, then spiked by 36.68% to -$218.3 million in 2022, then surged by 109.45% to $20.6 million in 2023, then skyrocketed by 103.21% to $41.9 million in 2024.